Anti-miRNA-based therapeutics for Mammary, ovarian, renal & liver cancer: The OncomiR miR-17-92 suppresses the expression of BDGI via down regulation of its target gene, 15/May/2014, 5.09 am

Anti-miRNA-based therapeutics for Mammary, ovarian, renal & liver cancer: The OncomiR miR-17-92 suppresses the expression of BDGI via down regulation of its target gene, 15/May/2014, 5.09 am

Anti-miRNA-based therapeutics for Mammary, ovarian, renal & liver cancer: The OncomiR miR-17-92 suppresses the expression of BDGI via down regulation of its target gene, 15/May/2014, 5.09 am 150 150 Dr Boomi's Genom-2-Discovery Center

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To cite: Boominathan, L., Anti-miRNA-based therapeutics for Mammary, ovarian, renal & liver cancer:  The OncomiR miR-17-92 suppresses the expression of BDGI via down regulation of its target gene, 15/May/2014, 5.09 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

 

Share
Start Typing